ILDR2: A Potential Drug Target and Biomarker (G387597)

Target Name: ILDR2

NCBI ID: G387597

ILDR2

ILDR2: A Potential Drug Target and Biomarker

Immunoglobulin-like domain-containing receptor 2 (ILDR2) is a protein that is expressed in various tissues throughout the body. It is a member of the intercellular adhesion molecule (ICAM) family and is involved in cell-cell adhesion, as well as in the regulation of cell survival and angiogenesis. ILDR2 has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become an attractive target for drug development.

ILDR2 is a transmembrane protein that is characterized by the presence of an extracellular domain that is composed of a single alpha-helix. The protein has a molecular weight of approximately 180 kDa and is expressed in various tissues, including the liver, spleen, kidney, and brain. It is highly expressed in human tissues and has been shown to be involved in the development and progression of various diseases.

One of the key functions of ILDR2 is its role in cell-cell adhesion. ILDR2 is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue integrity and prevent the loss of cells. It is also involved in the regulation of cell survival and angiogenesis, as well as in the regulation of inflammation.

ILDR2 has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of ILDR2 are associated with the development of certain types of cancer, such as breast cancer and colon cancer. Additionally, research has suggested that ILDR2 may be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Despite these promising findings, the development of ILDR2-based drugs has been challenging. One of the main challenges is the difficulty of targeting the protein within the body, as ILDR2 is expressed in various tissues and is involved in the regulation of a wide range of physiological processes. Additionally, the study of ILDR2-based drugs has been limited by the lack of tools for the specific detection and quantification of the protein in various tissues.

In recent years, researchers have made significant progress in the study of ILDR2 and its potential as a drug target. One approach that has been explored is the use of small interfering RNA (siRNA) technology to knockdown the expression of ILDR2 in various tissues. This approach has allowed researchers to specifically reduce the amount of ILDR2 protein present in the body, making it easier to study its effects.

Another approach that has been explored is the use of antibodies to target ILDR2 directly within the body. This approach has allowed researchers to specifically detect and quantify the protein in various tissues, making it easier to study its effects.

In addition to these approaches, researchers have also been interested in studying the downstream signaling pathways that are involved in the regulation of ILDR2. This has led to the identification of several key signaling pathways that are involved in the regulation of ILDR2, including the TGF- 尾 pathway and the PI3K/Akt pathway.

Overall, ILDR2 is a protein that has significant implications for the development of drug targets and biomarkers. Its role in cell-cell adhesion, as well as its involvement in the regulation of cell survival and angiogenesis, make it an attractive target for drug development. Furthermore, the use of small interfering RNA and antibodies technology has allowed researchers to study its effects specifically within the body, and the identification of key signaling pathways that are involved in its regulation

Protein Name: Immunoglobulin Like Domain Containing Receptor 2

Functions: May be involved in ER stress pathways with effects on lipid homeostasis and insulin secretion. With ILDR1 and LSR, involved in the maintain of the epithelial barrier function through the recruitment of MARVELD2/tricellulin to tricellular tight junctions (By similarity). Also functions as a B7-like protein family member expressed on immune cells and inflamed tissue and with T-cell inhibitory activity (PubMed:29431694). In the inner ear, may regulate alternative pre-mRNA splicing via binding to TRA2A, TRA2B and SRSF1 (By similarity)

The "ILDR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ILDR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets